Free Trial
NASDAQ:OCUL

Ocular Therapeutix (OCUL) Stock Price, News & Analysis

Ocular Therapeutix logo
$8.83 +0.31 (+3.64%)
(As of 11/22/2024 ET)

About Ocular Therapeutix Stock (NASDAQ:OCUL)

Key Stats

Today's Range
$8.41
$8.88
50-Day Range
$8.46
$11.47
52-Week Range
$2.14
$11.77
Volume
819,876 shs
Average Volume
947,681 shs
Market Capitalization
$1.39 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.71
Consensus Rating
Moderate Buy

Company Overview

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Ocular Therapeutix Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
74th Percentile Overall Score

OCUL MarketRank™: 

Ocular Therapeutix scored higher than 74% of companies evaluated by MarketBeat, and ranked 265th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Ocular Therapeutix has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Ocular Therapeutix has only been the subject of 2 research reports in the past 90 days.

  • Read more about Ocular Therapeutix's stock forecast and price target.
  • Earnings Growth

    Earnings for Ocular Therapeutix are expected to decrease in the coming year, from ($0.89) to ($1.00) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ocular Therapeutix is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ocular Therapeutix is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Ocular Therapeutix has a P/B Ratio of 3.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    8.06% of the outstanding shares of Ocular Therapeutix have been sold short.
  • Short Interest Ratio / Days to Cover

    Ocular Therapeutix has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Ocular Therapeutix has recently decreased by 4.45%, indicating that investor sentiment is improving.
  • Dividend Yield

    Ocular Therapeutix does not currently pay a dividend.

  • Dividend Growth

    Ocular Therapeutix does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.06% of the outstanding shares of Ocular Therapeutix have been sold short.
  • Short Interest Ratio / Days to Cover

    Ocular Therapeutix has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Ocular Therapeutix has recently decreased by 4.45%, indicating that investor sentiment is improving.
  • News Sentiment

    Ocular Therapeutix has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Ocular Therapeutix this week, compared to 5 articles on an average week.
  • Search Interest

    13 people have searched for OCUL on MarketBeat in the last 30 days. This is an increase of 44% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Ocular Therapeutix to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Ocular Therapeutix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,525.00 in company stock.

  • Percentage Held by Insiders

    Only 3.50% of the stock of Ocular Therapeutix is held by insiders.

  • Percentage Held by Institutions

    59.21% of the stock of Ocular Therapeutix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Ocular Therapeutix's insider trading history.
Receive OCUL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter.

OCUL Stock News Headlines

Ocular Therapeutix Reports Q3 2024 Financial Results
Ocular Therapeutix (OCUL) Gets a Buy from Scotiabank
⭕ [URGENT] Buy Alert just triggered
My absolute favorite stock just hit a critical "buy now" trigger price.
Ocular Therapeutix price target raised to $15 from $14 at H.C. Wainwright
Q3 2024 Ocular Therapeutix Inc Earnings Call
See More Headlines

OCUL Stock Analysis - Frequently Asked Questions

Ocular Therapeutix's stock was trading at $4.46 at the beginning of 2024. Since then, OCUL shares have increased by 98.0% and is now trading at $8.83.
View the best growth stocks for 2024 here
.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) posted its quarterly earnings data on Wednesday, August, 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.04. The company's revenue was up 7.9% on a year-over-year basis.

Top institutional investors of Ocular Therapeutix include State Street Corp (2.23%), Geode Capital Management LLC (2.10%), Assenagon Asset Management S.A. (1.81%) and Deltec Asset Management LLC (1.67%). Insiders that own company stock include Summer Road Llc, Antony C Mattessich, Sanjay Nayak, Donald Notman, Philip C Strassburger, Christopher G White and Rabia Gurses Ozden.
View institutional ownership trends
.

Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ocular Therapeutix investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Marinus Pharmaceuticals (MRNS) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
8/07/2024
Today
11/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OCUL
Employees
267
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.71
High Stock Price Target
$22.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+89.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-80,740,000.00
Net Margins
-283.74%
Pretax Margin
-283.74%

Debt

Sales & Book Value

Annual Sales
$61.44 million
Book Value
$2.24 per share

Miscellaneous

Free Float
151,714,000
Market Cap
$1.39 billion
Optionable
Optionable
Beta
1.26

Social Links

10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:OCUL) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners